These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 4042444)

  • 21. Impact of lowering dialysate calcium concentration on serum bone turnover markers in hemodialysis patients.
    Hamano T; Oseto S; Fujii N; Ito T; Katayama M; Horio M; Imai E; Hori M
    Bone; 2005 May; 36(5):909-16. PubMed ID: 15794928
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Use of calcium carbonate (CaCO3) as phosphate binder in dialysis patients in long-term follow-up over 3 years].
    Sperschneider H; Günther K; Stein G; Marzoll I; Kirchner E
    Z Urol Nephrol; 1990 Aug; 83(8):449-58. PubMed ID: 2122612
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The requirement of low calcium dialysate in patients on continuous ambulatory peritoneal dialysis receiving calcium carbonate as a phosphate binder.
    Cheng IK; Lu HB; Chan CY; Cheng SW; Robinson JD; Tam SC; Lo WK; Cheung WC
    Clin Nephrol; 1993 Aug; 40(2):100-5. PubMed ID: 8222365
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The effects of zero magnesium dialysate and magnesium supplements on ionised calcium concentration in patients on regular dialysis treatment.
    Breuer J; Moniz C; Baldwin D; Parsons V
    Nephrol Dial Transplant; 1987; 2(5):347-50. PubMed ID: 3122112
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The effects of calcium carbonate as the sole phosphate binder in combination with low calcium dialysate and calcitriol therapy in chronic hemodialysis patients.
    Oettinger CW; Oliver JC; Macon EJ
    J Am Soc Nephrol; 1992 Oct; 3(4):995-1001. PubMed ID: 1450373
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of calcium carbonate and aluminium hydroxide as phosphate binders on biochemical bone markers, PTH(1-84), and bone mineral content in dialysis patients.
    Jespersen B; Jensen JD; Nielsen HK; Lauridsen IN; Andersen MJ; Poulsen JH; Gammelgaard B; Pedersen EB
    Nephrol Dial Transplant; 1991; 6(2):98-104. PubMed ID: 1857534
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Low serum aluminum values in dialysis patients with increased bone aluminum levels.
    van Landeghem GF; D'Haese PC; Lamberts LV; Djukanovic L; Pejanovic S; Goodman WG; De Broe ME
    Clin Nephrol; 1998 Aug; 50(2):69-76. PubMed ID: 9725776
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and side-effect profile of sevelamer hydrochloride used in combination with conventional phosphate binders.
    Sturtevant JM; Hawley CM; Reiger K; Johnson DW; Campbell SB; Burke JR; Bofinger A; Isbel NM
    Nephrology (Carlton); 2004 Dec; 9(6):406-13. PubMed ID: 15663645
    [TBL] [Abstract][Full Text] [Related]  

  • 29. RenaGel efficacy in severe secondary hyperparathyroidism.
    Castro R; Herman A; Ferreira C; Travassos F; Nunes-Azevedo J; Oliveira M
    Nefrologia; 2002; 22(5):448-55. PubMed ID: 12497746
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Substitution of calcium carbonate for aluminum hydroxide in patients on hemodialysis. Effects on acidosis, on parathyroid function, and on calcemia.
    Anelli A; Brancaccio D; Damasso R; Padovese P; Gallieni M; Garella S
    Nephron; 1989; 52(2):125-32. PubMed ID: 2500612
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy of combined sevelamer and calcium carbonate therapy for hyperphosphatemia in Japanese hemodialysis patients.
    Iwasaki Y; Takami H; Tani M; Yamaguchi Y; Goto H; Goto Y; Goto Y; Shigematsu T
    Ther Apher Dial; 2005 Aug; 9(4):347-51. PubMed ID: 16076380
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A randomized trial comparing 2.5 mEq/L calcium dialysate and calcitriol to 3.5 mEq/L calcium dialysate in patients on peritoneal dialysis.
    Banalagay E; Bernardini J; Holley J; Chen T; Piraino B
    Adv Perit Dial; 1993; 9():280-3. PubMed ID: 8105943
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Long-term effect of different dialysate calcium concentrations on parathyroid hormone levels in hemodialysis patients.
    Hwang JC; Chen CA; Wang CT; Chen HC
    Ren Fail; 2008; 30(10):943-51. PubMed ID: 19016144
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-term effects of calcium carbonate and 2.5 mEq/liter calcium dialysate on mineral metabolism.
    Slatopolsky E; Weerts C; Norwood K; Giles K; Fryer P; Finch J; Windus D; Delmez J
    Kidney Int; 1989 Nov; 36(5):897-903. PubMed ID: 2615197
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sevelamer controls parathyroid hormone-induced bone disease as efficiently as calcium carbonate without increasing serum calcium levels during therapy with active vitamin D sterols.
    Salusky IB; Goodman WG; Sahney S; Gales B; Perilloux A; Wang HJ; Elashoff RM; Jüppner H
    J Am Soc Nephrol; 2005 Aug; 16(8):2501-8. PubMed ID: 15944337
    [TBL] [Abstract][Full Text] [Related]  

  • 36. 1 alpha(OH) vitamin D3 increases plasma aluminum in hemodialized patients taking AI(OH)3.
    Demontis R; Leflon A; Fournier A; Tahiri Y; Herve M; Moriniere P; Abdull-Massih Z; Atik H; Belbrik S; Renaud H
    Clin Nephrol; 1986 Sep; 26(3):146-9. PubMed ID: 3769230
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Treatment of hyperphosphatemia in chronic renal failure].
    Babarykin DA; Afanas'eva GA; Shul'man OM; Luse LIa; Rozental' RL
    Ter Arkh; 1984; 56(7):64-6. PubMed ID: 6484838
    [No Abstract]   [Full Text] [Related]  

  • 38. [Role of the time of administration of calcium carbonate (before or during mealtime) in the control of hyperphosphatemia in patients on maintenance hemodialysis].
    Séchet A; Abighanem O; Said S; Rasombololona M; Morinière P; Brazier M; Fournier A
    Nephrologie; 1999; 20(4):209-12. PubMed ID: 10480153
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Usefulness of calcium acetate as a chelating of phosphorus in patients in hemodialysis with secondary hyperthyroidism].
    Torregrosa Prats JV; Mas Mas M; Montesinos Ballestena M; Casellas Bartumeus J; Campistol Plana JM
    An Med Interna; 1995 Aug; 12(8):377-81. PubMed ID: 8924527
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Hemodialysis with 2.5 mEq/L of calcium in relative hypoparathyroidism: long-term effects on bone mass].
    Sánchez Perales MC; García Cortés MJ; Borrego FJ; Fernández Martínez S; Borrego J; Pérez del Barrio P; Liébana A; Pérez Bañasco V
    Nefrologia; 2000; 20(3):254-61. PubMed ID: 10917002
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.